Pharmaceutical - Markets & Marketing, Metabolics


Popular Filters

Orexigen earns total $100 million milestone on Contrave

Orexigen earns total $100 million milestone on Contrave


US biopharma company Orexigen Therapeutics says it has earned a $70 million milestone payment from partner…

ContraveFinancialMarkets & MarketingMetabolicsOrexigen TherapeuticsPharmaceuticalTakeda PharmaceuticalUSA

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022


Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December


Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Eisai's launch plan for obesity drug Belviq in USA enters consumer phase


The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Market for obesity therapies to reach a value of $2.6 billion in 2019


The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report


The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

It's official: "obesity is a disease," says AMA


The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Arena/Eisai's Belviq at last to launch in the USA


USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that its long-awaited weight loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Par Pharma agrees $45 million settlement over off-label Megace ES promotion


US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

Vivus announces new discount program for obesity drug Qsymia


US drugmaker Vivus (Nasdaq: VVUS) has announced a new program offering eligible patients a discount on…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalPricingQsymiaVivus

Express Scripts adds Vivus' Qsymia to its standard benefits program


US drugmaker Vivus (Nasdaq: VVUS) says that Express Scripts, among the USA's largest Pharmacy Benefit…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Arena Pharma links with Ildong for Belviq marketing in South Korea


USA-based Arena Pharmaceuticals (Nasdaq: ARNA) has entered into a marketing and supply agreement with…

Arena PharmaceuticalsAsia-PacificBelviqIldong PharmaLicensingMarkets & MarketingMetabolicsPharmaceutical

Hyperparathyroidism therapeutics market to reach $2.62 billion by 2019


Hyperparathyroidism (HPT) patients can expect a slow but steady change in treatment options, as pharmaceutical…

Markets & MarketingMetabolicsPharmaceuticalResearch

Strong start for Vivus' obesity drug Qsymia; deal with Express Scripts


Sales of US drugmaker Vivus' (Nasdaq: VVUS) obesity agent Qsymia (phentermine and topiramate extended-release)…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Vivus debuts weight-loss pill Qsymia on US market


USA-based Vivus (Nasdaq: VVUS) saw its shares rise 3.9% to $22.93 on Monday, after the company announced…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Vivus' Qsymia set to be most widely used emerging therapy for obesity treatment


Novel emerging agents will experience rapid uptake owing to the high prevalence of obese or overweight…

Arena PharmaceuticalsBelviqMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

CASiGEN Pharma created in Hong Kong to bring new potential diabetes treatments to global market


USA-based Ventac Partners and the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences…

Asia-PacificCASiGEN PharmaDiabetesMarkets & MarketingMetabolicsPharmaceuticalResearch

Back to top